Seeking efficiency in executive compensation benchmarking?

Unlock Efficiency in Executive Compensation Benchmarking with CompAnalyst Executive

CompAnalyst Executive

The charts on this page feature a breakdown of the total annual pay for the top executives at AGIOS PHARMACEUTICALS as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. AGIOS PHARMACEUTICALS income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. AGIOS PHARMACEUTICALS annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Jacqualyn A. Fouse Ph.D.
Former Chief Executive Officer, Director
Total Cash $759,711 Equity $4,141,027 Other $10,311 Total Compensation $4,911,049
Jonathan Biller
Former Chief Financial Officer, Head of Corporate Affairs
Total Cash $388,850 Equity $1,077,700 Other $11,517 Total Compensation $1,478,067
Bruce Car Ph.D.
Former Chief Scientific Officer
Total Cash $309,429 Equity $1,077,700 Other $465,255 Total Compensation $1,852,384
Sarah Gheuens M.D., Ph.D.
Chief Medical Officer, Head of Research & Development
Total Cash $755,250 Equity $1,077,700 Other $13,953 Total Compensation $1,846,903
Richa Poddar
Former Chief Commercial Officer
Total Cash $450,000 Equity $1,077,700 Other $398,756 Total Compensation $1,926,456
Cecilia Jones
Chief Financial Officer
Total Cash $398,934 Equity $2,507,570 Other $4,422 Total Compensation $2,910,926
Brian Goff
Chief Executive Officer
Total Cash $753,539 Equity $10,981,074 Other $9,834 Total Compensation $11,744,447
James Burns
Chief Legal Officer
Total Cash $646,300 Equity $1,077,700 Other $14,025 Total Compensation $1,738,025
For its 2022 fiscal year, AGIOS PHARMACEUTICALS, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Brian Goff CEO Pay $12,504,158 Median Employee Pay $251,489 CEO Pay Ratio 50:1
For its 2022 fiscal year, AGIOS PHARMACEUTICALS, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Cynthia Smith Total Cash $745,355
David P. Schenkein, M.D. Total Cash $432,297
David Scadden, M.D. Total Cash $427,297
Ian T. Clark Total Cash $31,250
Jacqualyn A. Fouse, Ph.D. Total Cash $43,750
John M. Maraganore, Ph.D. Total Cash $452,297
Kaye Foster Total Cash $434,797
Maykin Ho, Ph.D. Total Cash $424,797
Paul J. Clancy Total Cash $433,547
Rahul Ballal, Ph.D. Total Cash $747,855

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.